For example, statins prevent atherosclerotic events more strongly in patients with higher levels of plasma inflammatory markers (e.g., C-reactive protein) at baseline58, and benefit of treatment with renin-angiotensin system (RAS) inhibitors or sacubitril-valsartan is larger in HF patients with reduced ejection fraction (HFrEF) than in those with preserved ejection fraction (HFpEF)59. The gene discussed is CRP; the disease is hydrops fetalis.